Free Newsletter
Novartis CEO mum on Bayer buyout
Novartis says it's not interested in merging with another Big Pharma player--but CEO Daniel Vasella (photo) still won't comment on a rumored takeover of German rival Bayer.
Vasella told a French newspaper that a merger isn't the answer to the company's skyrocketing R&D costs and less-than-skyrocketing revenues. But when asked point-blank about Bayer, he clammed up. Some stock analysts have pooh-poohed the notion of Novartis snapping up Bayer. Others, however, helped fuel the rumors, which have died down a bit lately. Vasella's "no comment" just may stir them up again.Â
- read the coverage from Forbes
Related Articles:
Rumor Mill: Novartis may bid for Bayer. Report
Cash-rich Novartis CEO mulls biotech buyouts. Report
Bayer plans to beef up biotech pipeline. Report
Novartis CEO critiques U.S. healthcare. Report
Comments
By Anonymous | Posted 3:03pm | July 31, 2008
Cancer Drug Gleevec Linked to Muscle Damage.
www.nlm.nih.gov/medlineplus/news/fullstory_65981.html
Because of Vasella chronic myelogenous leukemia is now a treatable chronic disease instead of a killer.
Is anyone surprised? NO!
Post new comment
Paid Research Reports
- The Specialty Pharma Market Outlook: Key players, new company growth models and emerging opportunities
- Investigating Clinical Trial Costs: Comparative analysis of trial cost components in key geographies
- Clinical Trial Recruitment Strategies: Optimizing patient recruitment and retention in late stage clinical trials
- Pipeline Insight: Therapeutic Cancer Vaccines - Prospect of first approval set to reinvigorate interest from major companies
- Stakeholder Opinions: Vaccines in Emerging Markets (Asia) - Opportunities in China, India, South Korea and Taiwan
- Big Pharma Performance Before, During and Beyond the Global Recession
SHARE
WITH: